OXYVIST
Live / Applied — First extension granted (statement of use) (as of 25 Nov 2025)
What this means for you
Not registered yet, but its 12 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98646705
- Mark type
- Stylized text
- Filed
- 12 Jul 2024
- Published for opposition
- 01 Apr 2025
- Attorney of record
- Rebecca Liebowitz
Goods and services
- Class 005 — Pharmaceuticals: Biometallic compounds for consumption and/or injection for use in medical imaging and for diagnostic purposes; Contrast media for in vivo imaging; Contrast media for in-vivo imaging; Contrast media for use with imaging medical equipment
Owner
- Surgisense Corporation, Bethesda, MD, US
- Surgisense Corporation, Bethesda, MD, US
Prosecution history
- 26 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Nov 2025 — SOU EXTENSION 1 GRANTED
- 25 Nov 2025 — SOU EXTENSION 1 FILED
- 25 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Mar 2025 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 12 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Mar 2025 — ASSIGNED TO LIE
- 24 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 31 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED